Different human cancers featured the benefit of targeting both ETAR and ETBR, in which ET-1R blockade with the dual ETAR/ETBR small molecule antagonists represents a suitable therapeutic option for ET-1R-expressing tumors. Here, EDNRB is linked to cancer.